Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
KRAS-targeted Drugs R&D Service

KRAS-targeted Drugs R&D Service

Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

KRAS-targeted Drugs R&D Service

RAS is one of the most frequently mutated oncogenes in human cancer. KRAS is the isoform most frequently mutated, which constitutes about 85% of RAS mutations. As the most frequently mutated RAS isoform, KRAS is intensively studied in the past years.

In the formulation of KRAS integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon provides KRAS-targeted drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services.

KRAS GTPase cycle.webp

Targeting the untargetable KRAS[1]

Introduction of KRAS
Structure of KRAS
Signal Pathway of KRAS Signaling
Crystallization Studies of KRAS Protein
In Vitro Studies of KRAS-targeted Drugs
Pharmacology Evaluation of KRAS-targeted Drugs
Pharmacokinetic (PK) Studies of KRAS-targeted Drugs
Medicilon Assisted Projects
Learn more about "KRAS-targeted Drugs R&D Service"
Relevant laboratories
prev page next page
  • Pharmacokinetics refrigerator
  • Immunoassay platform
  • RAD SOURCE Small Animal X-ray irradiator
  • Details of IVIS SPECTRUM 3D imager for small animals
  • BD FACSymphoy A3